Moderna vaccine can safely produce similar immunity for toddlers as it does young adults

Embargoed until: Publicly released: 2022-10-20 08:00

International

Photo by Mufid Majnun on Unsplash

The Moderna vaccine has a comparable efficacy in children aged 6 months to five years as it does in young adults despite a smaller dose being used for children, according to international research. As part of Moderna's ongoing phase 2-3 trial of their mRNA vaccine for young children, the researchers randomly assigned 3040 children aged 2-5 and 1762 children aged 6-23 months to receive the vaccine, and 1008 and 593 children respectively to receive a placebo. The researchers say two doses of the lower-dosage vaccine were found to be safe, with mainly low-grade side effects and no new safety concerns discovered.

Media release

From:

Attachments

Note: Not all attachments are visible to the general public. Research URLs will go live after the embargo ends.

Research Massachusetts Medical Society, Web page The URL will go live after the embargo ends

Journal/
conference: New England Journal of Medicine

Research:Paper

Organisation/s: Moderna, USA

Funder: Funded by the Biomedical Advanced Research and Development Authority and National Institute of Allergy and Infectious Diseases; KidCOVE ClinicalTrials.gov number, NCT04796896.

Media Contact/s

Contact details are only visible to registered journalists.